-
From A(erie) To Z(ynerba): Biotech Catalysts Lined Up For Second Half Of 2017
Friday, August 25, 2017 - 9:07am | 460Between late-stage readouts and regulatory events, the biotech industry has enough second-half catalysts to potentially actualize Cantor Fitzgerald’s investment theses and justify its price targets, according to the firm’s recent note. The most imminent is Versartis Inc (NASDAQ: VSAR)...
-
This Biotech Name Could Be Best In Breed For 2017
Tuesday, June 13, 2017 - 8:46am | 879The biotech sector has seen better times this year after the disappointing showing in 2016. Calithera Biosciences Inc (NASDAQ: CALA) has been a stand-out performer in the sector, clocking gains in excess of 300 percent in the year-to-date period. But, does it qualify for the tag "best-in-...
-
Big Short Interest On These 5 Biotech Stocks
Monday, January 12, 2015 - 4:36pm | 688Rumor has it that if the S&P 500 finishes its first five trading days of the year with a gain, then the year in question will -- 80 percent of the time -- end with a gain as well. Last Thursday’s rally gave the S&P that five-day gain. However, since that day, the market has seen a...
-
Why Gilead Sciences, Inc. Is A Top Mutual Fund Holding
Friday, September 5, 2014 - 9:27am | 502The ongoing Ebola epidemic has refocused the world's attention on biotechs, as the ZMapp serum, from San Diego's Mapp Biopharmaceutical, helped treat two American infectees earlier this year. That's not the only thing the space has going for it, though. VC Investment Is...
-
4 Ebola Researching Biotech Companies For Your Portfolio
Thursday, August 7, 2014 - 9:15am | 896With the death toll from West Africa’s Ebola outbreak reaching close to 1,000, serious interest is being taken into researching compounds that could both prevent outbreak and help those infected. Until recently, Ebola was a pretty rare disease, Dr. Jim Wilson told Benzinga, and the...
-
BioMarin Weathers The Storm
Wednesday, August 6, 2014 - 4:02pm | 389In last week’s Benzinga article on InterMune (NASDAQ: ITMN), some of the warning signs for the overall stock market were highlighted. Those warnings became more than just warnings last week, as the market took some significant hits. Last Thursday’s 300-plus drop on the Dow Jones...
-
4 ETFs With Upside Potential
Wednesday, July 2, 2014 - 10:08am | 527ETF Outlook for Wednesday, July 2, 2014 iShares NASDAQ Biotech Index ETF (NASDAQ: IBB) The March-April sell-off that wiped out large gains in the biotech sector is now in the rear view mirror and IBB is back to the best level since March. The ETF is up over 22 percent since mid-April when the...
-
Biogen Raises Full-Year Earnings, But Is That The Entire Picture?
Thursday, April 24, 2014 - 5:03pm | 686One of the best performers in the incredible bull run for the market has been the biotech sector. Many of the stocks in the sector have doubled, tripled, quadrupled and, in the case of Biogen (NASDAQ: BIIB), decupled (ten times) in price. BIIB, which bottomed in Nov. 2008 ($37.21) and peaked...
-
Biotech ETFs Come Back Down To Earth
Thursday, March 27, 2014 - 4:29pm | 483Biotech stocks have been one of the hottest sectors of the market over the last several years and many exchange traded funds have benefitted greatly from their success. The two largest ETFs in this space are the iShares NASDAQ Biotechnology ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSE:...
-
Amarin's Vascepa: Too Limited A Market Or FDA Blunder?
Wednesday, December 18, 2013 - 3:11pm | 1018Is Amarin's (NASDAQ: AMRN) Vascepa the victim of its own ineptitude, or the target of an effort by Big Pharma to keep it off the market? Those questions and others have been lobbed around lately by a variety of industry observers and investors, regarding Amarin's sole product, Vascepa – a...
-
Small-Cap Corner: A Forgotten Biotech ETF
Thursday, July 5, 2012 - 6:11pm | 614Perhaps the most impressive secular story of 2012 has been the performance of the biotechnology sector. Spurred by a spate of new drug approvals, positive trial data, and mergers and acquisitions activity, the biotech group has proven immune to U.S. and European macroeconomic headwinds. Beyond...
-
NASDAQ Biotech Market Gainers; (BPAX), (CELG), (GILD) Stocks to Watch
Tuesday, November 2, 2010 - 2:08pm | 939Point Roberts, WA –November 2, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, features a Biotech /Pharma Sector Trading Snapshot featuring some of the NASDAQ's market gainers in today's trading.. Gilead...
-
Big Meeting Could Mean Big Gains For Biotech Investors
Tuesday, June 8, 2010 - 1:40pm | 200While the World Cup Kicks off in South Africa, biotech investors are having their own world class event. The American Society of Clinical Oncology (ASCO) kicked off this June 4th and will run until today. This is the most important meeting for the biotech sector and is attended by doctors and...
-
Mid Cap Biotechs May Outperform In 2010
Friday, January 15, 2010 - 3:11pm | 230Analysts at Cowen and Company say that their expectation for a strong earnings season is underlined by positive fluctuations in foreign currency, favorable seasonal demand trends and a continued open pricing environment. Cowen and Company expects emerging product companies to offer profit-making...